Waters Corporation Reports Strong Q1 2026 Results and Raises Full-Year Guidance

Details

Organic revenue grew 13% as reported and 11% in constant currency, driven by strong performance in the Analytical Sciences Division. The Biosciences and Diagnostic Solutions businesses contributed $520 million in revenue since the acquisition closing, $40 million above guidance. GAAP EPS was ($0.87), while adjusted EPS was $2.70, growing 20% year-over-year. The company raised its full-year 2026 organic constant currency revenue growth guidance to 6.5% to 8.0% and adjusted EPS guidance to $14.40 to $14.60.

Items reported

About Waters Corporation

Waters Corporation is a leading entity in the field of analytical instruments and software. It primarily focuses on providing laboratory solutions for a variety of sectors, including pharmaceuticals, healthcare, food and beverage, and chemical analysis. The company's offerings include high-performance liquid chromatography, mass spectrometry systems, and various supporting technologies used for advanced research in life sciences. Waters Corporation is pivotal in enhancing laboratory productivity, offering cutting-edge research tools that assist in drug development, quality control, and environmental testing. Operating globally, it serves a wide array of clients, including academic institutions, government agencies, and private industry players. With its commitment to innovation and precision, Waters Corporation plays a crucial role in advancing scientific and technological progress in multiple critical industries worldwide.